Direct and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment - Université Paris Cité Access content directly
Journal Articles Frontiers in Immunology Year : 2021

Direct and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment

Abstract

Vascular endothelial growth factor A is known to play a central role in tumor angiogenesis. Several studies showed that VEGF-A is also an immunosuppressive factor. In tumorbearing hosts, VEGF-A can modulate immune cells (DC, MDSC, TAM) to induce the accumulation of regulatory T-cells while simultaneously inhibiting T-cell functions. Furthermore, VEGFR-2 expression on activated T-cells and FoxP3 high regulatory T-cells also allow a direct effect of VEGF-A. Anti-angiogenic agents targeting VEGF-A/VEGFR contribute to limit tumor-induced immunosuppression. Based on interesting preclinical studies, many clinical trials have been conducted to investigate the efficacy of anti-VEGF-A/VEGFR treatments combined with immune checkpoint blockade leading to the approvement of these associations in different tumor locations. In this review, we focus on the impact of VEGF-A on immune cells especially regulatory and effector T-cells and different therapeutic strategies to restore an antitumor immunity.
Fichier principal
Vignette du fichier
fimmu-12-616837.pdf (508.41 Ko) Télécharger le fichier
Origin : Publication funded by an institution

Dates and versions

hal-03788530 , version 1 (26-09-2022)

Identifiers

Cite

Morgane Bourhis, Juliette Palle, Isabelle Galy-Fauroux, Magali Terme. Direct and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment. Frontiers in Immunology, 2021, 12, pp.616837. ⟨10.3389/fimmu.2021.616837⟩. ⟨hal-03788530⟩

Collections

INSERM UP-SANTE
39 View
34 Download

Altmetric

Share

Gmail Facebook X LinkedIn More